STERIS plc's Stock Analysis

STERIS plc Announces Financial Results and Executive Changes

On August 6, 2025, STERIS plc reported a 9% increase in total revenue for the first quarter of fiscal 2026, reaching $1.4 billion. Net income from continuing operations also grew to $177.4 million, or $1.79 per diluted share, compared to $139.8 million, or $1.41 per diluted share, in the same quarter of the previous year. The Healthcare segment saw an 8% revenue increase, while the Applied Sterilization Technologies segment reported a 13% rise. The company expects revenue growth to be between 8-9% for fiscal 2026, influenced by favorable foreign currency rates, although tariffs are projected to negatively impact profits by approximately $45 million.

In leadership changes, Michael J. Tokich resigned as Chief Financial Officer, with his role transitioning to a senior financial advisor until March 2026. Karen Burton will assume the CFO position effective August 18, 2025, with a base salary of $600,000 and a target bonus opportunity of 75% of her salary. The company also announced changes to its Board of Directors, including the election of Louis Shapiro. The annual meeting of shareholders confirmed the appointment of Ernst & Young as the company’s independent registered public accounting firm for the upcoming fiscal year.

Aug 06, 2025 16:39:15

Dr. Richard Steeves to Retire from STERIS Board

Dr. Richard Steeves has announced his retirement from the Board of Directors of STERIS plc, effective July 31, 2025, coinciding with the Company's Annual General Meeting of Shareholders. He will not seek re-election at this meeting, concluding a decade of service on the Board.

The Company confirmed that Dr. Steeves' retirement is not due to any disagreements regarding its strategy, operations, policies, or practices. The Board and the Company expressed their gratitude for his contributions during his tenure.

Jul 03, 2025 16:30:29

Dr. Richard Steeves to Retire from STERIS Board in 2025

Dr. Richard Steeves has announced his retirement from the Board of Directors of STERIS plc, effective July 31, 2025, coinciding with the Company's Annual General Meeting of Shareholders. He will not seek re-election at this meeting. Dr. Steeves' decision is not due to any disagreements regarding the Company’s strategy or operations, and the Company expresses gratitude for his decade of service on the Board.

The announcement of Dr. Steeves' retirement comes as part of a routine transition within the Board. His tenure as a Director has spanned 10 years, and his departure may prompt considerations regarding the future composition of the Board and its potential impact on company governance and direction.

Jul 03, 2025 16:30:29

STERIS Reports Fiscal 2025 Financial Results and Outlook

STERIS plc announced its financial results for the fourth quarter and full year of fiscal 2025, reporting a 6% increase in revenue from continuing operations, totaling $5.5 billion. The diluted earnings per share (EPS) from continuing operations rose to $6.16, while adjusted EPS increased to $9.22. In the fourth quarter alone, revenue from continuing operations reached $1.5 billion, reflecting a 4% increase compared to the same period last year, with a constant currency organic revenue growth of 6%. The company reported net income from continuing operations of $146.5 million for the fourth quarter, down slightly from $152.9 million in the prior year, but adjusted net income increased to $270.3 million from $240.1 million year-over-year.

Looking ahead, STERIS provided an outlook for fiscal 2026, expecting a revenue increase of 6-7% from continuing operations. The company anticipates that adjusted earnings per diluted share will range from $9.90 to $10.15, representing a 7-10% increase compared to the previous fiscal year. The outlook also includes a negative impact from tariffs, estimated to reduce pre-tax profit by approximately $30 million. Free cash flow for fiscal 2026 is projected to be around $770 million, with capital expenditures expected to be approximately $375 million.

May 14, 2025 16:34:06

STERIS Reports $1.4 Billion Revenue in Q3 Fiscal 2025

STERIS plc announced a 6% increase in total revenue from continuing operations for the third quarter of fiscal 2025, reaching $1.4 billion, up from $1.3 billion in the same period last year. The company reported earnings per share (EPS) from continuing operations increased to $1.75, with adjusted EPS rising to $2.32. Healthcare revenue grew by 7%, driven by significant improvements in consumable and service revenue, although capital equipment revenue saw a decline of 5%. The Applied Sterilization Technologies segment also experienced a 10% revenue increase, while the Life Sciences segment reported a 7% decrease in revenue due to a divestiture and declining capital equipment sales. Cash flow from operations for the first nine months of fiscal 2025 was $887.3 million, up from $718.5 million in the previous year, contributing to a free cash flow increase to $588.1 million from $457.0 million last year.

Conversely, STERIS updated its fiscal 2025 outlook, now expecting revenue growth of approximately 6%, a reduction from earlier expectations of 6.5% to 7.5%. This adjustment was primarily attributed to unfavorable currency impacts and lower anticipated capital equipment revenue in the Healthcare segment. The adjusted earnings per diluted share forecast was also slightly lowered to a range of $9.05 to $9.15, reflecting about a ten-cent negative currency impact. Additionally, the Life Sciences segment faced challenges with a 7% revenue decline, largely due to the divestiture of a business unit and decreased capital equipment sales.

Feb 05, 2025 16:33:40

STERIS Reports $1.3 Billion Revenue in Q2 2025

STERIS plc reported a 7% increase in total revenue from continuing operations for the second quarter of fiscal 2025, reaching $1.3 billion compared to $1.2 billion in the same quarter of the previous year. The company also saw a rise in net income, which was $150.2 million or $1.51 per share, up from $119.8 million or $1.20 per share in the prior year. Notably, healthcare revenue grew by 9%, driven mainly by a significant increase in consumable and service revenues, although capital equipment revenue saw a slight decline. The company reiterated its fiscal 2025 outlook, indicating confidence in continued growth across its business segments, particularly in healthcare and applied sterilization technologies.

On the downside, STERIS faced challenges in its Life Sciences segment, where revenue decreased by 4% due to the divestiture of a business segment. This decline was attributed to a significant drop in capital equipment and service revenues, despite a growth in consumable revenue. Additionally, the Applied Sterilization Technologies segment reported a slight decline in operating income compared to the previous year, attributed to rising labor and energy costs, as well as a loss from a capital equipment sale. Overall, while the company demonstrated growth in several areas, it also highlighted sector-specific challenges that may impact future performance.

Nov 06, 2024 16:45:21

Company Report Submission and Compliance Update

The company has submitted its financial statements and exhibits as required, indicating a commitment to transparency and regulatory compliance. It has also noted that certain schedules and attachments have been omitted but can be provided to the Securities and Exchange Commission upon request, which demonstrates a willingness to cooperate with regulatory bodies.

The press release highlights the signing of the report by J. Adam Zangerle, confirming the authenticity of the submission. This step underscores the company's adherence to the necessary legal obligations, although the omission of certain details could raise questions about the completeness of the information provided.

Oct 07, 2024 16:57:32

STERIS Reports Strong Q1 Growth and Reiterates Outlook

STERIS plc announced an 8% revenue increase in Q1 2025, reaching $1.3 billion, with adjusted earnings per share rising to $2.03. Healthcare revenue grew 10%, driven by consumables and services, although capital equipment revenue declined. The Life Sciences segment saw a slight revenue drop due to a recent divestiture. Overall, STERIS remains confident in its fiscal 2025 outlook, expecting continued revenue growth and strong cash flow.

Aug 06, 2024 16:47:42

STERIS Fiscal 2024 Results and Restructuring Plan

STERIS reports a 12% revenue increase in fiscal 2024, with adjusted earnings per share rising to $8.83. The company plans a $100 million restructuring, aiming for $25 million annual EBIT improvement. Fiscal 2025 revenue is forecasted to grow 6.5-7.5%. Divesting the Dental segment, the Healthcare segment showed strong performance. Free cash flow surged to $620.3 million in fiscal 2024 from $409.6 million in the prior year.

May 08, 2024 16:49:47

STERIS Sells Dental Segment to Peak Rock Capital

STERIS plc is selling its Dental segment to Peak Rock Capital for $787.5 million to focus on core markets like healthcare. The divestiture will help reduce debt and increase interest expense benefit by approximately $0.35 per diluted share. STERIS aims to support its core markets better with its full range of products and services. The transaction is expected to close in the first quarter of fiscal 2025, subject to regulatory review.

Apr 11, 2024 07:22:35